OD
Highly rated in
39
conditions

Dr. Orrin Devinsky

NYU Langone Comprehensive Epilepsy Center
New York, NY
Highly rated in
39
conditions
Specialties:Neurology | General Surgery
Experience:41 Years
Clinical Trials:Currently Recruiting for 8 Trials
Accepts:New PatientsMedicare
Highly rated in
39
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Orrin Devinsky's experience treating your condition:
About Dr. Orrin Devinsky

Orrin Devinsky is a Neurologist and a General Surgeon in New York, New York. Devinsky has been practicing medicine for over 41 years and is highly rated in 39 conditions, according to our data. His top areas of expertise are Dravet Syndrome, Seizures, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Deep Brain Stimulation. He is licensed to treat patients in New Jersey and New York. Devinsky is currently accepting new patients.

His clinical research consists of co-authoring 451 peer reviewed articles and participating in 13 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Orrin Devinsky it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Orrin Devinsky accepts the following insurance:

  •  Ambetter
Call to see if your plan is accepted.
Locations
223 E 34th St, New York, NY 10016
Background & Education
Graduate Institution
Harvard Medical School, 1982
Specialties
Neurology
General Surgery
Licenses
Psychiatry & Neurology in NJ
Hospital Affiliations
Tisch Hospital
St Peters Hospital
Lehigh Valley Hospital - Pocono
NewYork-Presbyterian Hudson Hospital
Cooperman Barnabas Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase 2 Study of Cannabidiol as a New Treatment for Autism Spectrum Disorder in Children and Adolescents
Enrollment Status: Recruiting
Publish Date: August 02, 2022
Intervention Type: Drug
Study Drug: Cannabidiol
Study Phase: Phase 2
Risk Factors for Sudden Unexplained Death in Epilepsy (SUDEP)
Enrollment Status: Recruiting
Publish Date: March 25, 2022
Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy
Enrollment Status: Recruiting
Publish Date: May 16, 2022
The SUDC Registry and Research Collaborative
Enrollment Status: Recruiting
Publish Date: March 23, 2022
Intervention Type: Other
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Recruiting
Publish Date: April 12, 2022
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Enrollment Status: Recruiting
Publish Date: September 27, 2022
Intervention Type: Biological, Procedure
Study Drug: NRTX-1001
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 2
Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Other
Study Phase: Not Applicable
A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drug: Ganaxolone
Study Phase: Phase 2
Fenfluramine in CKDL5 Deficiency Disorder (CDD)
Enrollment Status: Enrolling by invitation
Publish Date: April 07, 2022
Intervention Type: Drug
Study Drug: Fenfluramine hydrochloride
Study Phase: Phase 2
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Enrollment Status: Completed
Publish Date: September 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials -
453 Total Publications
Publisher Correction: Viral manipulation of functionally distinct interneurons in mice, non-human primates and humans.
Journal: Nature neuroscience
Published: August 09, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
HK
Dr. Horacio C. Kaufmann
Neurology
Highly rated in
21
conditions
Neurology

NYU Langone Health

NYC Health And Hospitals - Bellevue

462 1st Ave, 
New York, NY 
 0.4 mi

Horacio Kaufmann is a Neurologist in New York, New York. Kaufmann has been practicing medicine for over 44 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, and Multiple System Atrophy. He is licensed to treat patients in New York.

FI
Dr. Fabio M. Iwamoto
Neurology
Highly rated in
16
conditions
Neurology

NewYork-Presbyterian Healthcare System

ColumbiaDoctors Midtown

51 W 51st St, 
New York, NY 
 1.0 mi

Fabio Iwamoto is a Neurologist in New York, New York. Iwamoto has been practicing medicine for over 23 years and is highly rated in 16 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. He is licensed to treat patients in New York. Iwamoto is currently accepting new patients.

ED
Dr. Eli L. Diamond
Neurology
Highly rated in
21
conditions
Neurology

Memorial Sloan Kettering Cancer Center

430 E 67th St, 
New York, NY 
 1.6 mi

Eli Diamond is a Neurologist in New York, New York. Diamond has been practicing medicine for over 15 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Erdheim-Chester Disease, Glioma, Brain Tumor, and Glioblastoma. He is licensed to treat patients in New York. Diamond is currently accepting new patients.